Michael Atkin is listed as an executive officer and director on 2 SEC Form D filings by 1 issuer between Jun 2015 and Nov 2018: Gladius Pharmaceuticals Corp (Wilmington, DE — biotechnology — 2015–2018; $3.02M reported sold to 5 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Daniel Hetu (1 shared filing), Jens Eckstein (1 shared filing), Larry Sutton (1 shared filing) and Nathalie Chauret (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 5 bankruptcy cases matching the name listed in Key records below.
What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Michael Atkin and found 4 differences: Michael Atkin's role changed at Gladius Pharmaceuticals Corp: executive officer, director → executive officer; Industry group changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.